In Stock
Mesala 400 mg Tablet (Delayed Release), 1 strip
Tk70
- Stock: In Stock
- Brand: NIPRO JMI Pharma Ltd.
- Product ID: Mesalazine [5-aminosalicylic acid]
0 Pcs sold
2738 Interested
100% Secure Payment
This Item is for pre order
Estimated Delivery in
Mesala 400 mg Tablet (Delayed Release), 1 strip
Description:
Mesala 400 (Mesalazine) is an orally administered delayed release tablet. Mesalazine diminishes inflammatory bowel disease by blocking cyclooxygenase and inhibiting prostaglandin synthesis in the colon.
Indication
Mesala 400 tablet is indicated for the treatment of inflammatory bowel diseases like ulcerative colitis and Crohn’s disease.
Dosage & Administration
Treatment of mild to moderate Ulcerative Colitis: Adult: Recommended dosage is 800 mg (two 400 mg tablets) three times daily for a duration of 6 weeks. Child (5 years of age and older): Daily dosage of Mesala 400 is as follows:
Maintenance dosage for Ulcerative Colitis: The recommended dosage in adult is 1.6 grams (four 400 mg tablets) daily in two to four divided doses.
Maintenance of remission of Crohn’s disease: Child (12-17 years): 400-800 mg 2-3 times a day Adult: 1.2 - 2.4 g daily in divided doses
Body weight | Morning Dosage | Evening Dosage | Duration |
17-33kg | Two 400 mg tablets | One 400 mg Tablet | 6 weeks |
33 – 54 Kg | Three 400 mg tablets | One 400 mg Tablet | 6 weeks |
Maintenance of remission of Crohn’s disease: Child (12-17 years): 400-800 mg 2-3 times a day Adult: 1.2 - 2.4 g daily in divided doses
Contraindication
Mesalazine is contraindicated in patients with known hypersensitivity to the active ingredient or any other components of the formulation.
Precaution
Evaluate the risk and benefits in patients with known renal and hepatic impairment during treatment. Monitoring is required in Mesalazine-induced Acute Intolerance Syndrome. Discontinue Mesalazine if this type of syndrome is suspected.
Side Effects
The most common side effects are eructation, abdominal pain, constipation, dizziness, rhinitis, back pain and rash. Nasopharyngitis, headache, abdominal pain, dizziness, sinusitis, rash, cough and diarrhea are observed in children.
Drug Interaction
Nephrotoxic agents i.e. NSAIDs: increases risk of nephrotoxicity; So, monitoring is required. Azathioprine or 6-Mercaptopurine: Increases risk of blood disorders; monitoring of complete blood cell counts and platelet counts is required.
Pregnancy & Lactation
There are no adequate and well controlled studies in pregnant women and lactating mother therefore, it should be given in pregnancy and lactation only if the potential benefit justifies the potential risk to the fetus or children.
Storage Condition
Keep in a cool & dry place (below 30o C), protected from light & moisture. Keep out of the reach of children.